Please refer to the discussion under the heading ‘Factors Affecting Future Operating Results ‘in the Management Discussion and Analysis of Financial Condition and results of operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ended 30 September 2006. For a full discussion of these and other risks Genzyme cautions investors not to heavy reliance on the forward-looking statements in this press release to exit. These statements are only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements..
We are very pleased with these results, add the growing body of evidence for Synvisc and reflect our commitment to continued innovation on behalf of patients and physicians encouraging, said Ann Merrifield, president of Genzyme Biosurgery Division. We believe that the benefits of Synvisc through an administrative rather than three additional options for physicians and patients, the cost and burden of multiple injections. . Read More